Myeloid Leukemia, Chronic Clinical Trial
Official title:
Dendritic Cells as Autologous Vaccine in Patients With Chronic Myeloid Leukemia
The aim of this phase I/II trial is induction of anti leukemic T cell immunity in a clinical situation of "minimal residual disease". This might be a strategy to immunologically eradicate the residual leukemia cells. Patients to be included are chronic phase bcr/abl+ CML (chronic myeloid leukemia) patients in stable cytogenetic and/or molecular remission. These patients can be included if they have: 1. not achieved a CMR (complete molecular response) or 2. achieved bcr/abl < 10% on qPCR (quantitative polymerase chain reaction) (=MCyR) (Major cytogenic Response), but less than a CCyR (complete cytogenic Response). Autologous DC (Dendritic cells), generated under GMP (Good manufacturing conditions) conditions, are used as a vaccine. These DC constitutively express all putative tumor antigens. In order to ensure sufficient presentation of distinct CML-related antigens, particularly in good responders to TKIs, DC are additionally pulsed with peptides from bcr/abl, WT-1 (Wilms Tumor Protein) and proteinase-3. Monitoring of T cell reactivity against these peptides can then serve as surrogate marker for anti leukemic immunity induced by the vaccine. Vaccination is performed with 10^7 DC i.d. (intra dermal) in weeks 1, 3, 5, 8, 11, 14, 17, 20, 23 and 26. KLH (keyhole limpet hemocyanin) is used as an adjuvant for vaccine preparations in weeks 3, 5 and 8 (and 11).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00114959 -
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
|
Phase 2 | |
| Completed |
NCT00482703 -
A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Terminated |
NCT02086487 -
Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy
|
Phase 4 | |
| Recruiting |
NCT00445822 -
Registration of Children With CML and Treatment With Imatinib
|
N/A | |
| Completed |
NCT00478985 -
Evaluation of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia
|
N/A | |
| Terminated |
NCT00210119 -
Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response
|
Phase 2 | |
| Completed |
NCT02222272 -
Effect of 2nd Gen TKI in CML
|
||
| Completed |
NCT01660607 -
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
|
Phase 1/Phase 2 | |
| Completed |
NCT02890784 -
Dasatinib Holiday for Improved Tolerability
|
Phase 3 | |
| Completed |
NCT00481247 -
A Phase III Study of Dasatinib vs. Imatinib in Patients With Newly Diagnosed Chronic Phase CML
|
Phase 3 |